Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects

BACKGROUND: Bortezomib is an FDA-approved proteasome inhibitor, and oncolytic HSV-1 (oHSV) is a promising therapeutic approach for cancer. We tested the impact of combining bortezomib with oHSV for anti-tumor efficacy. METHODS: The synergistic interaction between oHSV and bortezomib was calculated u...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Yoo, Ji Young, Hurwitz, Brian S, Bolyard, Chelsea, Yu, Jun-Ge, Zhang, Jianying, Selvendiran, Karuppaiyah, Rath, Kellie S, He, Shun, Bailey, Zachary, Eaves, David, Cripe, Timothy P, Parris, Deborah S., Caligiuri, Michael A., Yu, Jianhua, Old, Matthew, Kaur, Balveen
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4132885/
https://ncbi.nlm.nih.gov/pubmed/24815720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0553
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares